HanchorBio Expands Global Presence Through Key Presentations
Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio will be featured at major oncology congresses.
HanchorBio, Inc. (TPEx: 7827), a pioneering global biotechnology company dedicated to transformative immunotherapies, has unveiled a dynamic lineup of scientific presentations at renowned international oncology conferences throughout the first quarter of the year. The extensive selection of abstracts, highlighted by several prestigious oral presentations, illustrates the clinical progression and esteemed scientific recognition of HanchorBio's proprietary pipeline.
These upcoming presentations will showcase insights from HanchorBio's leading clinical programs, notably the HCB101-101 Phase 1 monotherapy and the HCB101-201 Phase 1b/2a combination studies. Also on display will be data from the HCB301-101 Phase 1 monotherapy study, emphasizing the innovative potential of its CD47-SIRP? innate immune backbone and multi-functional biologics.
Key Innovations in HanchorBio's Pipeline
The forefront of HanchorBio's advances includes:
HCB101
This highly engineered SIRP?–IgG4 Fc-fusion protein aims to enhance phagocytosis while minimizing the risk of hematologic toxicities. Its unique design reinforces its clinical viability by preserving macrophage-mediated antitumor activity and selectively targeting cancer cells.
HCB301
HCB301 stands out as a first-in-class multi-specific candidate that strategically targets crucial pathways such as CD47/SIRP?, PD-1/PD-L1, and TGF-beta. This approach aims to mitigate the immunosuppressive tumor microenvironment, boosting the efficacy of oncological treatments.
Event Highlights for Q1 2026
Following the successful presentation of promising outcomes for HCB101 in treating second-line gastric cancer, HanchorBio is set to continue unveiling significant clinical findings at various prestigious events:
Conferences and Presentations
The upcoming schedule includes:
- ASCO GI Cancers Symposium - Completed
- AACR Immuno-Oncology - Upcoming in Los Angeles
- Asia-Pacific GI Cancer Congress - Upcoming in Okinawa
- ESMO Targeted Anticancer Therapies - Upcoming in Paris
- ESMO Head and Neck Congress - Upcoming in Seville
- World Oncology Congress - Upcoming in Paris
These scheduled appearances underscore HanchorBio's commitment to advancing its clinical agenda and sharing vital research outcomes with the global oncology community.
Innovative Product Overview
About HCB101
HCB101, a next-generation SIRP? Fc-fusion protein, was crafted on HanchorBio's FBDB™ platform to efficiently block the CD47–SIRP? innate immune checkpoint. Its design aims to preserve essential immune functions while mitigating adverse reactions associated with traditional CD47-targeted therapies. The development leverages AI-assisted modeling, distinguishing itself through specific binding on cancer cells with minimal interaction with red blood cells.
This distinctive mechanism enhances the efficacy of ongoing clinical evaluations, demonstrating early signs of tumor reduction in multiple challenging cancer types.
About HCB301
HCB301 combines three critical immunotherapeutic mechanisms into one agent: CD47-SIRP? blockade to activate myeloid phagocytosis, PD-1 inhibition to rejuvenate T cell activity, and TGF-beta pathway suppression to combat immune evasion. Its unique properties pave the way for enhanced antitumor responses, as evidenced by preclinical studies that have showcased potent immune activation.
About HanchorBio
HanchorBio operates on an ambitious platform dedicated to crafting innovative immunotherapies. Headquartered across key cities globally, the company’s leadership consists of seasoned professionals with a strong history in biologics and healthcare. With a focus on developing multifunctional biologics through the FBDB™ platform, HanchorBio aims to harness both innate and adaptive immune responses to address persistent difficulties associated with current cancer therapies. The company is set to propel a portfolio aimed at fulfilling significant unmet medical needs through pioneering strategies in research and development.
Frequently Asked Questions
What is HanchorBio's primary focus?
HanchorBio primarily focuses on developing innovative immuno-oncology therapies that enhance patient outcomes in cancer treatment.
What are HCB101 and HCB301?
HCB101 is a SIRP? Fc-fusion protein designed for efficient cancer targeting, while HCB301 integrates multiple checkpoint inhibitors to enhance immune responses.
Where will HanchorBio be presenting their findings?
HanchorBio will present at renowned conferences including AACR Immuno-Oncology and ESMO Targeted Anticancer Therapies.
What distinguishes HCB101 from earlier therapies?
HCB101 is engineered to minimize safety concerns by reducing interactions with red blood cells, a common issue with traditional anti-CD47 treatments.
How does HanchorBio address unmet medical needs?
HanchorBio designs biologics targeting both innate and adaptive immunity to provide more effective treatment options for a range of cancers.
